Advertisement

Acute Transverse and Flaccid Myelitis in Children

  • Liana M. Theroux
  • J. Nicholas BrentonEmail author
Multiple Sclerosis and Related Disorders (J Graves, Section Editor)
  • 38 Downloads
Part of the following topical collections:
  1. Topical Collection on Multiple Sclerosis and Related Disorders

Abstract

Purpose of review

The etiologies of myelitis in children are broad, and our understanding of inflammatory myelopathies in the pediatric population continues to evolve. Acute flaccid myelitis (AFM), increasingly linked to enterovirus infections, has risen in incidence over recent years. As with other infectious myelopathies, AFM can be challenging to distinguish from inflammatory causes of acute transverse myelitis (ATM) at initial presentation. This review outlines an approach to the treatment of children presenting with myelopathy of suspected inflammatory etiology, with attention to how management may differ in the specific case of acute flaccid myelitis.

Recent findings

Although high-quality evidence is limited, intravenous corticosteroids, intravenous immunoglobulin, and plasma exchange have important roles in the acute management of ATM. Spinal cord injury in AFM, though similar to ATM in clinical presentation, is largely mediated by direct infection as opposed to a primary inflammatory process, and treatment with corticosteroids may worsen outcomes.

Summary

Awareness of the distinguishing clinical features of AFM and the underlying inflammatory conditions that commonly manifest with ATM is essential to judicious selection of appropriate acute (and potentially chronic) therapies in children presenting with myelitis.

Keywords

Pediatric transverse myelitis Acute flaccid myelitis Inflammatory myelopathy Enterovirus Treatment 

Notes

Compliance with Ethical Standards

Conflict of Interest

Liana M. Theroux declares no potential conflicts of interest.

J. Nicholas Brenton reports personal fees for consulting for Novartis.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    • Banwell B, Kennedy J, Sadovnick D, Arnold DL, Magalhaes S, Wambera K, et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology. 2009;72(3):232–9. An epidemiologic study that provides incidence of pediatric acquired demyelinating syndromes (including ATM) in a large Canadian cohort.PubMedCrossRefGoogle Scholar
  2. 2.
    •• Absoud M, Greenberg BM, Lim M, Lotze T, Thomas T, Deiva K. Pediatric transverse myelitis. Neurology. 2016;87(9 Suppl 2):S46–52. A relatively recent review of pediatric transverse myelitis that provides more overview of its clinical features and outcomes.PubMedCrossRefGoogle Scholar
  3. 3.
    Greenberg BM, Thomas KP, Krishnan C, Kaplin AI, Calabresi PA, Kerr DA. Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology. 2007;68(19):1614–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Christy A, Messacar K. Acute flaccid myelitis associated with Enterovirus D68: a review. J Child Neurol. 2019;34(9):511–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Brown DM, Hixon AM, Oldfield LM, Zhang Y, Novotny M, Wang W, et al. Contemporary circulating Enterovirus D68 strains have acquired the capacity for viral entry and replication in human neuronal cells. MBio. 2018;9(5):e01954–18.Google Scholar
  6. 6.
    Holroyd KB, Aziz F, Szolics M, Alsaadi T, Levy M, Schiess N. Prevalence and characteristics of transverse myelitis and neuromyelitis optica spectrum disorders in the United Arab Emirates: a multicenter, retrospective study. Clin Exp Neuroimmunol. 2018;9(3):155–61.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Absoud M, Lim MJ, Chong WK, De Goede CG, Foster K, Gunny R, et al. Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features. Multiple sclerosis (Houndmills, Basingstoke, England). 2013;19(1):76–86.CrossRefGoogle Scholar
  8. 8.
    • Deiva K, Absoud M, Hemingway C, Hernandez Y, Hussson B, Maurey H, et al. Acute idiopathic transverse myelitis in children: early predictors of relapse and disability. Neurology. 2015;84(4):341–9. This study employed one of the largest cohorts of pediatric ATM cases to determine prognostic factors of relapse and future disability.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Thomas T, Branson HM, Verhey LH, Shroff M, Stephens D, Magalhaes S, et al. The demographic, clinical, and magnetic resonance imaging (MRI) features of transverse myelitis in children. J Child Neurol. 2012;27(1):11–21.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    • De Goede CG, Holmes EM, Pike MG. Acquired transverse myelopathy in children in the United Kingdom—a 2 year prospective study. Eur J Paediatr Neurol. 2010;14(6):479–87. This is a prospective population-based surveillance study from the UK that helped to define the incidence and outcomes of ATM in children.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    • Pidcock FS, Krishnan C, Crawford TO, Salorio CF, Trovato M, Kerr DA. Acute transverse myelitis in childhood: center-based analysis of 47 cases. Neurology. 2007;68(18):1474–80. This is a retrospective cohort study of ATM that provides important data on the clinical characteristics of children with ATM and their ultimate neurologic outcomes.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Defresne P, Hollenberg H, Husson B, Tabarki B, Landrieu P, Huault G, et al. Acute transverse myelitis in children: clinical course and prognostic factors. J Child Neurol. 2003;18(6):401–6.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Alper G, Petropoulou KA, Fitz CR, Kim Y. Idiopathic acute transverse myelitis in children: an analysis and discussion of MRI findings. Mult Scler. 2011;17(1):74–80.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Ayscue P, Van Haren K, Sheriff H, Waubant E, Waldron P, Yagi S, et al. Acute flaccid paralysis with anterior myelitis—California, June 2012-June 2014. MMWR Morb Mortal Wkly Rep. 2014;63(40):903–6.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Van Haren K, Ayscue P, Waubant E, Clayton A, Sheriff H, Yagi S, et al. Acute flaccid myelitis of unknown etiology in California, 2012-2015. Jama. 2015;314(24):2663–71.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Kane MS, Sonne C, Zhu S, Malhotra A, Van Haren K, Messacar K, et al. Incidence, risk factors and outcomes among children with acute flaccid myelitis: a population-based cohort study in a California Health Network between 2011 and 2016. Pediatr Infect Dis J. 2019;38(7):667–72.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Andersen EW, Kornberg AJ, Freeman JL, Leventer RJ, Ryan MM. Acute flaccid myelitis in childhood: a retrospective cohort study. Eur J Neurol. 2017;24(8):1077–83.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    •• Elrick MJ, Gordon-Lipkin E, Crawford TO, Van Haren K, Messacar K, Thornton N, et al. Clinical subpopulations in a sample of North American children diagnosed with acute flaccid myelitis, 2012-2016. JAMA Pediatr. 2019;173(2):134–39.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Messacar K, Schreiner TL, Van Haren K, Yang M, Glaser CA, Tyler KL, et al. Acute flaccid myelitis: a clinical review of US cases 2012-2015. Ann Neurol. 2016;80(3):326–38.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Greninger AL, Naccache SN, Messacar K, Clayton A, Yu G, Somasekar S, et al. A novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA (2012-14): a retrospective cohort study. Lancet Infect Dis. 2015;15(6):671–82.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Kuo SC, Cho WH, Shih HI, Tu YF. Idiopathic acute transverse myelitis in children: a retrospective series. Neuropediatrics. 2015;46(5):307–12.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Suthar R, Sankhyan N, Sahu JK, Khandelwal NK, Singhi S, Singhi P. Acute transverse myelitis in childhood: a single centre experience from North India. Eur J Paediatr Neurol. 2016;20(3):352–60.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Chitnis T, Ness J, Krupp L, Waubant E, Hunt T, Olsen CS, et al. Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. Neurology. 2016;86(3):245–52.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Bitnun A, Yeh EA. Acute flaccid paralysis and enteroviral infections. Curr Infect Dis Rep. 2018;20(9):34.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Dale RC, Brilot F, Banwell B. Pediatric central nervous system inflammatory demyelination: acute disseminated encephalomyelitis, clinically isolated syndromes, neuromyelitis optica, and multiple sclerosis. Curr Opin Neurol. 2009;22(3):233–40.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Majed M, Fryer JP, McKeon A, Lennon VA, Pittock SJ. Clinical utility of testing AQP4-IgG in CSF: guidance for physicians. Neurol Neuroimmunol Neuroinflamm. 2016;3(3):e231.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    •• Hennes EM, Baumann M, Schanda K, Anlar B, Bajer-Kornek B, Blaschek A, et al. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology. 2017;89(9):900–8. A large, prospective multicenter study that illustrates the prognostic value of MOG antibodies in children with acquired demyelinating syndromes, including ATM.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Bridel C, Courvoisier DS, Vuilleumier N, Lalive PH. Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of neurosarcoidosis. J Neuroimmunol. 2015;285:1–3.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Cassidy H, Poelman R, Knoester M, Van Leer-Buter CC, Niesters HGM. Enterovirus D68—the new polio? Front Microbiol. 2018;9:2677.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Messacar K, Tyler KL. Enterovirus D68-associated acute flaccid myelitis: rising to the clinical and research challenges. Jama. 2019; 321(9):831–23.PubMedCrossRefGoogle Scholar
  31. 31.
    •• Dubey D, Pittock SJ, Krecke KN, Morris PP, Sechi E, Zalewski NL, et al. Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol. 2019;76(3):301–9.PubMedCrossRefGoogle Scholar
  32. 32.
    • Tantsis EM, Prelog K, Alper G, Benson L, Gorman M, Lim M, et al. Magnetic resonance imaging in Enterovirus-71, myelin oligodendrocyte glycoprotein antibody, Aquaporin-4 antibody, and multiple sclerosis-associated myelitis in children. Dev Med Child Neurol. 2019;61(9):1108–16.CrossRefGoogle Scholar
  33. 33.
    Wang C, Narayan R, Greenberg B. Anti-myelin oligodendrocyte glycoprotein antibody associated with gray matter predominant transverse myelitis mimicking acute flaccid myelitis: a presentation of two cases. Pediatr Neurol. 2018;86:42–5.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Gordon-Lipkin E, Munoz LS, Klein JL, Dean J, Izbudak I, Pardo CA. Comparative quantitative clinical, neuroimaging, and functional profiles in children with acute flaccid myelitis at acute and convalescent stages of disease. Dev Med Child Neurol. 2019;61(3):366–75.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Verhey LH, Branson HM, Makhija M, Shroff M, Banwell B. Magnetic resonance imaging features of the spinal cord in pediatric multiple sclerosis: a preliminary study. Neuroradiology. 2010;52(12):1153–62.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Zalewski NL, Flanagan EP. Autoimmune and paraneoplastic myelopathies. Semin Neurol. 2018;38(3):278–89.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Brenton JN, Banwell BL. Therapeutic approach to the management of pediatric demyelinating disease: multiple sclerosis and acute disseminated encephalomyelitis. Neurotherapeutics. 2016;13(1):84–95.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    • Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;77(24):2128–34. The most recent guidelines regarding the treatment of ATM, as provided by the American Academy of Neurology.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Defresne P, Meyer L, Tardieu M, Scalais E, Nuttin C, De Bont B, et al. Efficacy of high dose steroid therapy in children with severe acute transverse myelitis. J Neurol Neurosurg Psychiatry. 2001;71(2):272–4.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Nosadini M, Mohammad SS, Suppiej A, Sartori S, Dale RC. Intravenous immunoglobulin in paediatric neurology: safety, adherence to guidelines, and long-term outcome. Dev Med Child Neurol. 2016;58(11):1180–92.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Absoud M, Gadian J, Hellier J, Brex PA, Ciccarelli O, Giovannoni G, et al. Protocol for a multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin versus standard therapy for the treatment of transverse myelitis in adults and children (STRIVE). BMJ Open. 2015;5(5):e008312.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Absoud M, Brex P, Ciccarelli O, Diribe O, Giovannoni G, Hellier J, et al. A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE). Health Technol Assess. 2017;21(31):1–50.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Manguinao M, Krysko KM, Maddike S, Rutatangwa A, Francisco C, Hart J, et al. A retrospective cohort study of plasma exchange in central nervous system demyelinating events in children. Mult Scler Relat Disord. 2019;35:50–4.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Bigi S, Banwell B, Yeh EA. Outcomes after early administration of plasma exchange in pediatric central nervous system inflammatory demyelination. J Child Neurol. 2015;30(7):874–80.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Llufriu S, Castillo J, Blanco Y, Ramio-Torrenta L, Rio J, Valles M, et al. Plasma exchange for acute attacks of CNS demyelination: predictors of improvement at 6 months. Neurology. 2009;73(12):949–53.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Noland DK, Greenberg BM. Safety and efficacy of plasma exchange in pediatric transverse myelitis. Neurol Clin Pract. 2018;8(4):327–30.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Baca V, Lavalle C, Garcia R, Catalan T, Sauceda JM, Sanchez G, et al. Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus. J Rheumatol. 1999;26(2):432–9.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Sloka JS, Stefanelli M. The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2005;11(4):425–32.CrossRefGoogle Scholar
  49. 49.
    Rossi F, Dietrich G, Kazatchkine MD. Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses. Immunol Rev. 1989;110:135–49.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Centers for Disease Control and Prevention (CDC). Acute flaccid myelitis: interim considerations for clinical management. 2018. https://www.cdc.gov/acute-flaccid-myelitis/hcp/clinical-management.html
  51. 51.
    • Martin JA, Messacar K, Yang ML, Maloney JA, Lindwall J, Carry T, et al. Outcomes of Colorado children with acute flaccid myelitis at 1 year. Neurology. 2017;89(2):129–37. A report on the outcomes in children with AFM in a Colorado cohort.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Nelson GR, Bonkowsky JL, Doll E, Green M, Hedlund GL, Moore KR, et al. Recognition and management of acute flaccid myelitis in children. Pediatr Neurol. 2016;55:17–21.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Hopkins SE, Elrick MJ, Messacar K. Acute flaccid myelitis—keys to diagnosis, questions about treatment, and future directions. JAMA Pediatr. 2019;173(2):117–8.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Zhang Y, Moore DD, Nix WA, Oberste MS, Weldon WC. Neutralization of Enterovirus D68 isolated from the 2014 US outbreak by commercial intravenous immune globulin products. J Clin Virol. 2015;69:172–5.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Hammon WM. Limitations in the use of gamma globulin in poliomyelitis. Am J Med Sci. 1953;226(2):125–30.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    •• Hixon AM, Clarke P, Tyler KL. Evaluating treatment efficacy in a mouse model of Enterovirus D68-associated paralytic myelitis. J Infect Dis. 2017;216(10):1245–53. A comprehensive description of the efficacy of various treatment modalities in a mouse model of AFM.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Shen FH, Shen TJ, Chang TM, Su IJ, Chen SH. Early dexamethasone treatment exacerbates Enterovirus 71 infection in mice. Virology. 2014;464-465:218–27.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    • Messacar K, Sillau S, Hopkins SE, Otten C, Wilson-Murphy M, Wong B, et al. Safety, tolerability, and efficacy of fluoxetine as an antiviral for acute flaccid myelitis. Neurology. 2019;92(18):e2118–e26. Class IV evidence that fluoxetine is not associated with improved neurologic outcomes in children with AFM due to EV-68.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Musharrafieh R, Ma C, Zhang J, Hu Y, Diesing JM, Marty MT, et al. Validating Enterovirus D68-2A(pro) as an antiviral drug target and the discovery of telaprevir as a potent D68-2A(pro) inhibitor. J Virol. 2019;93(7):e02221–18.Google Scholar
  60. 60.
    Rhoden E, Zhang M, Nix WA, Oberste MS. In vitro efficacy of antiviral compounds against Enterovirus D68. Antimicrob Agents Chemother. 2015;59(12):7779–81.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    • Hacohen Y, Banwell B. Treatment approaches for MOG-Ab-associated demyelination in children. Curr Treat Options Neurol. 2019;21(1):2. A recent review that focuses more specifically on a proposed treatment approach to children with MOG antibody-associated demyelination.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    • Gombolay GY, Chitnis T. Pediatric neuromyelitis optica spectrum disorders. Curr Treat Options Neurol. 2018;20(6):19. A recent review that focuses more specifically on the acute and chronic treatment of NMOSD.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Cappa R, Theroux L, Brenton JN. Pediatric multiple sclerosis: genes, environment, and a comprehensive therapeutic approach. Pediatr Neurol. 2017;75:17–28.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Saltzman EB, Rancy SK, Sneag DB, Feinberg Md JH, Lange DJ, Wolfe SW. Nerve transfers for Enterovirus D68-associated acute flaccid myelitis: a case series. Pediatr Neurol. 2018;88:25–30.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Morens DM, Folkers GK, Fauci AS. Acute flaccid myelitis: something old and something new. MBio. 2019;10(2):e00521–19.Google Scholar
  66. 66.
    Yi EJ, Shin YJ, Kim JH, Kim TG, Chang SY. Enterovirus 71 infection and vaccines. Clin Exp Vaccine Res. 2017;6(1):4–14.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Dai W, Zhang C, Zhang X, Xiong P, Liu Q, Gong S, et al. A virus-like particle vaccine confers protection against enterovirus D68 lethal challenge in mice. Vaccine. 2018;36(5):653–9.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Neurology, Division of Pediatric NeurologyUniversity of Virginia Health SystemCharlottesvilleUSA

Personalised recommendations